Chidozie Ugwumba Sells 37,235 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 37,235 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $5.94, for a total transaction of $221,175.90. Following the transaction, the insider owned 484,385 shares of the company’s stock, valued at approximately $2,877,246.90. This represents a 7.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total transaction of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The stock was sold at an average price of $6.33, for a total transaction of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The shares were sold at an average price of $6.61, for a total transaction of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The stock was sold at an average price of $6.31, for a total value of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total value of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The stock was sold at an average price of $6.79, for a total value of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The shares were sold at an average price of $6.81, for a total value of $74,276.67.
• On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The shares were sold at an average price of $6.42, for a total value of $63,692.82.
• On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The stock was sold at an average price of $5.95, for a total value of $89,434.45.
• On Monday, December 8th, Chidozie Ugwumba sold 21,463 shares of Clene stock. The shares were sold at an average price of $5.70, for a total transaction of $122,339.10.

Clene Stock Up 10.6%

Clene stock opened at $6.68 on Friday. The company has a 50 day moving average of $8.51 and a 200-day moving average of $6.21. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50. The stock has a market capitalization of $69.00 million, a PE ratio of -1.97 and a beta of 0.79.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Equities analysts anticipate that Clene Inc. will post -5.19 EPS for the current fiscal year.

More Clene News

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Sell‑side support remains — several research firms (Benchmark, UBS, D. Boral Capital) continue to carry Buy ratings and elevated targets, which can limit downside and support rebounds. MarketBeat CLNN
• Neutral Sentiment: Institutional activity mixed — some hedge funds increased or initiated positions (e.g., Scoggin Management added shares), meaning a portion of supply is being absorbed by institutions rather than retail. MarketBeat Holdings
• Negative Sentiment: Material insider selling by a major shareholder — Ugwumba disclosed many transactions from Dec. 3–17 totaling roughly ~258k shares sold across multiple days (including a 72,748 share sale on Dec. 4 that was reported as a 12.24% position reduction). Heavy, concentrated selling from a >10% holder puts clear downward pressure and likely explains the intraday weakness. InsiderTrades Article
• Negative Sentiment: Weak recent operating results — the company missed Q3 revenue and EPS expectations (reported -$0.85 vs. consensus -$0.60; revenue essentially immaterial), keeping the story speculative and increasing sensitivity to insider flows. SEC Filing

Analysts Set New Price Targets

CLNN has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research report on Tuesday, October 14th. Benchmark reissued a “buy” rating on shares of Clene in a research report on Thursday, December 4th. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of Clene in a research report on Wednesday, December 10th. Finally, UBS Group reiterated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Institutional Trading of Clene

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Scoggin Management LP grew its position in shares of Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after acquiring an additional 107,250 shares during the period. Lunt Capital Management Inc. grew its holdings in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares during the period. Jane Street Group LLC bought a new position in Clene during the second quarter worth about $47,000. Finally, Jones Financial Companies Lllp acquired a new position in Clene during the third quarter worth approximately $29,000. 23.28% of the stock is owned by institutional investors.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).